Skip to content

3D Reconstruction in Video-assisted Thoracoscopic Surgery (VATS) Segmentectomy

Three-dimensional Computed Tomography Reconstruction for Operative Planning in VATS Segmentectomy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04004494
Acronym
DRIVATS
Enrollment
191
Registered
2019-07-02
Start date
2019-07-01
Completion date
2023-12-31
Last updated
2024-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Segmentectomy

Keywords

segmentectomy, Video-assisted thoracoscopic surgery, lung cancer, ground-glass opacity

Brief summary

Anatomical variations of pulmonary vessel may cause serious problems during pulmonary segmentectomy. Three-dimensional (3D)computed tomography (CT) presents 3D images of pulmonary vessels and the tracheobronchial tree and may help operative planning. Retrospective studies have identified the importance of 3-dimensional CT in the field of pulmonary segmentectomy. And the aim of this study is to compare the usefulness of 3-dimensional CT with standard chest CT in preoperative planning of video-assisted segmentectomy.

Detailed description

Lung cancer has been the most serious malignancy around the world which has the highest morbidity and mortality amount all the malignant tumors. Due to the wide spread of lung cancer screening, more and more early stage lung cancer patients have been diagnosed. Video-assisted segmentectomy is a standard surgical procedure in treating early stage peripheral non-small cell lung cancer (NSCLC). However, anatomical variations of pulmonary vessel may cause serious problems, for example unexpected bleed during surgery. Three-dimensional computed tomography (CT), which is reconstructed based on the standard chest CT image, presents 3D images of pulmonary vessels and the tracheobronchial tree and therefore helps operative planning. There are several retrospective studies addressed the importance of 3-dimensional CT in the field of pulmonary segmentectomy. And the aim of this multicenter randomized controlled trial is to compare the usefulness of 3-dimensional CT and standard chest CT in preoperative planning of video-assisted segmentectomy.

Interventions

3-dimensional computed tomography reconstruction guided VATS segmentectomy

Sponsors

Union hospital of Fujian Medical University
CollaboratorOTHER
Guangdong Provincial People's Hospital
CollaboratorOTHER
Ruijin Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Parallel Assignment

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age older than 18 years; 2. Pulmonary nodules or ground glass opacification (GGO) found in chest CT examination, and conform with indications for segmentectomy: Peripheral nodule 0.8-2 cm with at least one of the following: i. Histology of adenocarcinoma in situ; ii. Nodule has ≥50% ground-glass appearance on CT; iii. Radiologic surveillance confirms a long doubling time (≥400 days). Segmentectomy should achieve parenchymal resection margins ≥2 cm or ≥ the size of the nodule. 3. Adequate cardiac function, respiratory function, liver function and renal function for anesthesia and VATS segmentectomy. 4. American Society of Anesthesiologists (ASA) score: Grade I-III. 5. Patients who can coordinate the treatment and research and sign the informed consent.

Exclusion criteria

1. Patients with a significant medical condition which is thought unlikely to tolerate the surgery. For example, cardiac disease, significant liver and renal function disorder. 2. Patients with psychiatric disease who are expected lack of compliance with the protocol. 3. Patients have history of chest trauma or surgery on ipsilateral chest which may cause pleural adhesion.

Design outcomes

Primary

MeasureTime frameDescription
operative timeDuring surgerythe time of operation

Secondary

MeasureTime frameDescription
blood lossDuring surgeryAmount of intraoperative blood loss
conversion rateDuring surgerythe rate of conversion to open surgery in the operation
operative accident eventDuring surgerythe accident event happened in operative. For example, a segmentectomy is converted to a lobectomy
Incidence of postoperative complicationsPostoperative in-hospital stay up to 30 daysmainly include: pneumonia, arrhythmia, incision infection, vocal cord paralysis, trachea cannula
Postoperative hospital stayUp to 24 weekslength of stay in hospitalization
Duration of chest tube placementUp to 4 weeksDuration of chest tube placement
30-day mortalityPostoperative in-hospital stay up to 30 days30-day mortality after surgery
Postoperative lung functionat the 3rd month after surgeryforced expiratory volume at one second(FEV1) in litre, maximal voluntary ventilation (MVV) in litre
Incidence of change of surgical planDuring surgerySurgical plan is made based of the image of standard chest computed tomography or three-dimensional computed tomography, the targeted segmental bronchus and pulmonary vessels are decided preoperatively. Change of surgical plan is recorded when the actually resected bronchus and vessels are different to those in the preoperative surgical plan
dissection of lymph nodes2 weeks after surgeryincluding overall lymph node count, number of stations dissected and number of lymph nodes in each lymph node station
Overall survival (OS)up to 60 monthsUp to the date of death of any causes since the date of randomization
Disease-free survival (DFS)up to 60 monthsUp to the date of disease recurrence since the date of randomization
Preoperative lung functionBaselineforced expiratory volume at one second(FEV1) in litre, maximal voluntary ventilation (MVV) in litre

Other

MeasureTime frameDescription
Total hospitalization expenditurespostoperative in-hospital stay up to 30 dayscost in hospital
Anatomical variationsDuring surgeryRate of anatomical variation of segmental bronchus and pulmonary vessel in Chinese population

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026